AI accelerates drug discovery but entrenches extractive pharmaceutical paradigms, sidelining systemic innovation and equitable access
Original framing: “AI is reengineering drug discovery by speeding up testing and scanning petabytes of data” — Phys.org
Future scenarios for AI in drug discovery range from utopian (democratized access to personalized medicine) to dystopian (corporate monopolies on life-saving treatments). A plausible middle path involves open-source AI models trained on diverse, culturally inclusive datasets, coupled with global equity frameworks like the WHO's mRNA technology transfer hub. However, current trends suggest a consolidation of power in the hands of a few tech-pharma conglomerates, with AI exacerbating existing disparities in healthcare access. Scenario planning must account for climate change, which will increase demand for drugs targeting vector-borne diseases, yet AI's energy-intensive training may conflict with sustainability goals.
The narrative of AI as a revolutionary force in drug discovery obscures its role in entrenching extractive pharmaceutical paradigms, where profit motives override public health needs.
Historically, the industry has exploited marginalized communities and indigenous knowledge, a pattern now repeating in the digital age through data colonialism and patent regimes. Cross-culturally, alternatives like Cuba's socialist biotech model or Ayurvedic systemic healing offer viable pathways, yet these are sidelined in favor of Silicon Valley's 'move fast and break things' ethos. The scientific community's focus on speed and scalability ignores the reproducibility crises and bias in AI-generated drug candidates, while future scenarios range from utopian open-source models to dystopian monopolies controlled by a handful of tech-pharma conglomerates. True systemic change requires decolonizing AI training data, shifting to public ownership of R&D, and centering marginalized voices—otherwise, AI will merely accelerate the same inequities it claims to solve. Actors like the NIH, WHO, and Indigenous-led organizations must lead this transformation, but their current influence is dwarfed by the lobbying power of Big Pharma and Big Tech.